An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Renal Cell Cancer
Both
Renal Cell Cancer
Trial Information
An Open Label, Prospective, Observational, Local, Non-interventional Study of BeVacizumab (Avastin) and IntErpherone (IFN) Alpha 2a in Patients With Metastatic and Locally Advanced Renal Cell CAncer (VERA Study)
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Histologically confirmed metastatic renal cell cancer, clear cell type
- Eligible for treatment with Avastin and interferon alpha 2a according to local
prescribing information
Exclusion Criteria:
- Contraindications for Avastin or interferon alpha 2a treatment according to local
Summary of Product Characteristics
- Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Progression-free survival
Outcome Time Frame:
approximately 4 years
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Romania: National Agency of Medicine and Medical Devices (MAMMD)
Study ID:
ML25255
NCT ID:
NCT01392729
Start Date:
September 2010
Completion Date:
October 2014
Related Keywords:
- Renal Cell Cancer
- Carcinoma, Renal Cell
Name | Location |
|---|
